124 related articles for article (PubMed ID: 19579616)
1. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma.
Isoda N; Eguchi Y; Nukaya H; Hosho K; Suga Y; Suga T; Nakazawa S; Sugano K
Hepatogastroenterology; 2009; 56(90):437-41. PubMed ID: 19579616
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer.
Shimizu K; Watanabe S; Watanabe S; Matsuda K; Suga T; Nakazawa S; Shiratori K
Hepatogastroenterology; 2009; 56(89):240-4. PubMed ID: 19453066
[TBL] [Abstract][Full Text] [Related]
3. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer.
Yoshino S; Watanabe S; Imano M; Suga T; Nakazawa S; Hazama S; Oka M
Hepatogastroenterology; 2010; 57(97):172-7. PubMed ID: 20422897
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer.
Hazama S; Watanabe S; Ohashi M; Yagi M; Suzuki M; Matsuda K; Yamamoto T; Suga Y; Suga T; Nakazawa S; Oka M
Anticancer Res; 2009 Jul; 29(7):2611-7. PubMed ID: 19596936
[TBL] [Abstract][Full Text] [Related]
5. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K
Hepatogastroenterology; 1999; 46(28):2662-8. PubMed ID: 10522061
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.
Yang P; Liang M; Zhang Y; Shen B
Adv Ther; 2008 Aug; 25(8):787-94. PubMed ID: 18670743
[TBL] [Abstract][Full Text] [Related]
8. [Effect of lentinan for advanced prostate carcinoma].
Tari K; Satake I; Nakagomi K; Ozawa K; Oowada F; Higashi Y; Negishi T; Yamada T; Saito H; Yoshida K
Hinyokika Kiyo; 1994 Feb; 40(2):119-23. PubMed ID: 8128920
[TBL] [Abstract][Full Text] [Related]
9. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer.
Oba K; Kobayashi M; Matsui T; Kodera Y; Sakamoto J
Anticancer Res; 2009 Jul; 29(7):2739-45. PubMed ID: 19596954
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.
Guiu B; Colin C; Cercueil JP; Loffroy R; Guiu S; Ferrant E; Jouve JL; Bonnetain F; Boulin M; Ghiringhelli F; Minello A; Hillon P; Bedenne L; Krause D; Chauffert B
Am J Clin Oncol; 2009 Jun; 32(3):238-44. PubMed ID: 19349854
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
13. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life.
Kataoka H; Shimura T; Mizoshita T; Kubota E; Mori Y; Mizushima T; Wada T; Ogasawara N; Tanida S; Sasaki M; Togawa S; Sano H; Hirata Y; Ikai M; Mochizuki H; Seno K; Itoh S; Kawai T; Joh T
Hepatogastroenterology; 2009; 56(90):547-50. PubMed ID: 19579640
[TBL] [Abstract][Full Text] [Related]
14. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
15. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.
Yu Y; Lang Q; Chen Z; Li B; Yu C; Zhu D; Zhai X; Ling C
Cancer; 2009 Nov; 115(22):5132-8. PubMed ID: 19672999
[TBL] [Abstract][Full Text] [Related]
16. [Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):387-93. PubMed ID: 6349538
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
18. [Change of blood lentinan level in patients with advanced cancers].
Yajima Y; Satoh J; Kikuchi T; Fukuda I; Toyota T; Saito H; Okabe N; Suzuki H
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2633-8. PubMed ID: 2774594
[TBL] [Abstract][Full Text] [Related]
19. Lentinan potentiates immunity and prolongs the survival time of some patients.
Matsuoka H; Seo Y; Wakasugi H; Saito T; Tomoda H
Anticancer Res; 1997; 17(4A):2751-5. PubMed ID: 9252710
[TBL] [Abstract][Full Text] [Related]
20. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Kawaoka T; Aikata H; Takaki S; Katamura Y; Hiramatsu A; Waki K; Takahashi S; Hieda M; Toyota N; Ito K; Chayama K
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):687-94. PubMed ID: 19444503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
